When businesses receive a proposal from a contract development and manufacturing organisation (CDMO), it’s much like a first date: first impressions matter. The proposal process not only reveals a CDMOs services but also hints at the potential relationship’s quality. This is gauged mainly through metrics like timing, quality, and price.
Clinical trials have to be coordinated as a safe process where monitoring, analytics and handling of patient samples is streamlined – even cross oceans. German MLM Medical Labs is quickly establishing itself as an emerging central and specialty lab in the U.S.
Within the competitive CDMO market, Richter-Helm has developed into a highly valued partner when it comes to the manufacturing of biopharmaceuticals. Richter-Helm is well recognised by pharmaceutical companies, including Big Pharma, as a professional partner offering flexible CDMO solutions from gene to product, all from one source, including consultancy services. This makes Richter-Helm one of the key players in CDMO business.
A well connected and effective infrastructure, a high density of research and development as well as close networking are of great value, not only to founders. Within the successful healthcare cluster Berlin-Brandenburg, these include numerous technology parks in the region. The parks offer optimal space including state of the art laboratories to start-up and grown-up companies.
Precision medicine tailors therapeutics to individual patients diseases, and is seen as the future of clinical practice. With significant time and financial investments being made in developing therapeutics, the ultimate success of patient-data driven precision therapies hinges on three main factors: the quality of the tissue samples, the associated molecular data, and the analysis used in their development.
After two years of unprecedented growth driven by the pandemic, investment attracted by Spanish biotech companies has stabilised, and they face significant challenges, positioning biotechnology as a strategic sector for Spain.
Depending on who you talk to, artificial intelligence (AI) is either a saviour or an enslaver. The concerns range from loss of jobs through to robots running society. However, in the life sciences, the use of AI and machine learning (ML) have created some excitement over their potential applications.
Conventional meat production contributes to 15% of the global greenhouse gas emissions, high energy consumption and land use change. Belgian Paleo NV produces alternative protein from myoglobins of different species.
Generic and biosimilar manufacturer Sandoz is expanding with a new biologics production facility in Lendava, Slovenia to prepare for more demand in Europe for biosimilar products.
The Sweden Biobank Act governs the collection, storage, and usage of identifiable human material samples for specific purposes.